Go to industries

Healthcare

Critical guidance on your journey

With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.

Contact advisor
Worldwide
518
deals closed in Healthcare
Worldwide
Explore all our industry-related deals
Go to deals
Muka Metal S.A. has been acquired by Stryker Corporation
Healthcare

Muka Metal S.A. has been acquired by Stryker Corporation

The private shareholders and owners of Muka Metal, A.S. have sold the company to Stryker Corporation. Financial details have not been disclosed.

Learn more
Olyos Group has acquired a controlling stake in NewScience
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more
Banook, backed by Motion Equity, has acquired Fluidda
Healthcare | TMT

Banook, backed by Motion Equity, has acquired Fluidda

Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.

Learn more
“Oaklins’ efforts enabled us to join Banook and significantly enhance our impact on respiratory drug development. Together with an outstanding transaction team, we were able to efficiently integrate into the Banook platform, backed by Motion Equity Partners.”

Jan De Backer

CEO, Fluidda NV

Read more
Example: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=de-AT&limit=3&tags=healthcare 
Ours: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=TR&includes=featured_images,tags&language=en&limit=1&tags=healthcare

New chapters, global ambitions: mid-market M&A in Q4

QUARTERLY M&A ACTIVITY: In Q4 2025, Oaklins' clients completed 93 transactions across sectors and regions, highlighting how business leaders are using M&A to drive growth, succession and strategic change.

Learn more

Talk to our local advisor

Levent Bosut

Managing Partner
Istanbul, Turkey
Oaklins inHERA

Meet our global industry specialists

Antoine Lemaire

Partner
Paris, France
Oaklins France

Stuart Goodman

Partner
London, United Kingdom
Oaklins S&W

Michael Jewell

Partner
London, United Kingdom
Oaklins Cavendish